Angiotensin-(1-7) enhances anti-aggregatory effects of the nitric oxide donor sodium nitroprusside
Date
2005
Authors
Rajendran, S.
Chirkov, Y.
Campbell, D.
Horowitz, J.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Journal of Cardiovascular Pharmacology, 2005; 46(4):459-463
Statement of Responsibility
Sharmalar Rajendran, Yuliy Y. Chirkov, Duncan J. Campbell, and John D. Horowitz
Conference Name
Abstract
Patients with ischemic heart disease have platelets that are resistant to the anti-aggregatory effects of nitric oxide (NO) donors. This NO resistance is associated with increased whole blood superoxide radical (O2−) content. Angiotensin II (Ang II) has been shown to augment O2− formation. Recent studies have demonstrated that angiotensin-(1-7) [Ang-(1-7)] has opposite actions to those of Ang II in the vasculature. This study compares the effects of Ang-(1-7) and Ang II on platelet aggregation and platelet responsiveness to the NO donor sodium nitroprusside (SNP). Platelet aggregation was induced by the thromboxane A2 mimetic U46619 (1-5 μmol/L), and the inhibitory effects of SNP (10 μmol/L) on the rate and extent of aggregation were quantified. Ang II did not induce aggregation, but 10-100 nmol/L Ang II potentiated U46619-induced aggregation by 21 ± 6% in the absence and by 26 ± 9% in the presence of SNP (P < 0.01 for both), in blood samples from 8 normal subjects. By contrast, Ang-(1-7) alone did not affect platelet aggregation, but 10-100 nmol/L Ang-(1-7) potentiated the anti-aggregatory effects of SNP in blood samples from both normal subjects (n = 17) and patients with acute coronary syndromes (n = 17). This effect of Ang-(1-7) was bimodal, and at higher concentrations of Ang-(1-7), potentiation was abolished. The maximum incremental effects of Ang-(1-7) on inhibition of aggregation were 25 ± 4% and 28 ± 5%, for rate and extent of aggregation respectively (P < 0.01 for both), corresponding to a 2.3-fold potentiation of the anti-aggregatory effect of SNP. Platelets from patients were resistant to the anti-aggregatory effect of SNP, but potentiation of SNP effects by Ang-(1-7) was similar for patients and normal subjects. Thus, Ang-(1-7) potentiates the anti-aggregatory effects of NO donor, and may therefore counteract platelet NO resistance that accompanies cardiovascular disease.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2005 Lippincott Williams & Wilkins, Inc.